Welcome to our dedicated page for Renovorx SEC filings (Ticker: RNXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RenovoRx, Inc. filings document the regulatory record of a life-sciences company commercializing RenovoCath® and developing targeted oncology therapies through its TAMP™ platform. Periodic and current reports disclose operating results, commercialization updates, clinical-trial strategy, and business updates related to the company’s investigational IAG drug-device candidate.
The company’s SEC record includes 8-K filings for financial results, material agreements, equity financings, warrant instruments, and at-the-market offering arrangements. Proxy materials cover annual meeting matters, board governance, executive compensation, and shareholder voting items, while leadership-related filings document officer appointments, compensatory arrangements, and reporting responsibilities.
VOLL MARK reported acquisition or exercise transactions in this Form 4 filing.
RenovoRx, Inc. reported that Chief Financial Officer Mark Voll received an award of 80,000 shares of Common Stock on April 3, 2026, reflecting stock-based compensation rather than an open-market purchase. The award stems from grants of restricted stock units for his service as CFO.
The footnote explains this consists of 8,777 RSUs for February 2026, 12,270 RSUs for March 2026, and 58,953 RSUs for future service, with the February and March RSUs fully vested upon grant and the remainder vesting monthly. After the transaction, he holds 117,380 shares directly and 97,200 shares indirectly through the Voll Family Trust.
RenovoRx, Inc. reported that Chief Clinical Officer Leesa Gentry received a grant of stock options to purchase up to 128,550 shares of common stock at an exercise price of $0.98 per share. The options vest over four years at a rate of 1/48 per month, with vesting starting on January 1, 2026, and becoming fully vested on January 1, 2030.
The options are exercisable only when there is an effective registration statement covering the underlying shares and will expire on April 3, 2036. Following this grant, Gentry holds 128,550 stock options directly.
RenovoRx, Inc. granted its Chief Medical Officer, Ramtin Agah, stock options to purchase 621,727 shares of common stock. The options have an exercise price of $0.98 per share and were approved by the Compensation Committee.
The grant consists of 319,073 shares underlying incentive stock options and 302,654 shares underlying non-qualified stock options. Vesting occurs over four years at 1/48 per month, beginning January 1, 2026, becoming fully vested on January 1, 2030. The options are exercisable only when there is an effective registration statement covering the underlying shares and will expire on April 3, 2036. Following this award, the reporting person holds 621,727 derivative securities.
RenovoRx reported full-year 2025 results and a business update. Revenue rose to $1.1 million from $43,000 in 2024, reflecting the first full year of RenovoCath commercialization across U.S. cancer centers. Net loss widened to $11.2 million from $8.8 million as the company invested in its Phase III TIGeR-PaC trial and commercial buildout.
Cash and cash equivalents were $7.0 million at December 31, 2025, and an oversubscribed March 2026 private placement added $10 million in gross proceeds, leaving about $13 million on hand. As of March 24, 2026, the TIGeR-PaC trial had randomized 104 patients with 72 events toward a 114-patient, 86-event target, and 12 cancer centers were actively using RenovoCath with additional centers in the pipeline.
RenovoRx, Inc. reports its annual results and business progress for the year ended December 31, 2025. The company generated $1.1 million in revenue from U.S. sales of its FDA‑cleared RenovoCath device, used for targeted intra‑arterial drug delivery in cancer care.
RenovoCath adoption is expanding, with 12 U.S. cancer centers using the device and a total of 33 centers requesting access, supported by more than 700 clinical procedures to date. RenovoRx is also advancing its TAMP therapy platform and IAG drug–device combination in the Phase III TIGeR‑PaC trial for locally advanced pancreatic cancer, where an initial interim analysis showed a 6‑month median overall survival benefit and over 65% fewer adverse events versus standard intravenous chemotherapy, leading the independent Data Monitoring Committee to recommend continuation.
VOLL MARK reported acquisition or exercise transactions in this Form 4 filing.
RenovoRx, Inc. chief financial officer Mark Voll reported an equity grant of 12,380 shares of common stock. These shares were granted as restricted stock units for his service as a consultant of the company for January 2026 and carry a stated price of $0.00 per share.
Following this grant, Voll directly holds 37,380 shares of common stock and has an additional 97,200 shares reported as indirectly held through the Voll Family Trust DTD 6/23/2010, with Mark Voll as trustee. This filing reflects compensation rather than an open-market stock purchase.
RenovoRx, Inc. filed an amended initial ownership report showing that Chief Financial Officer Mark Voll beneficially owns 25,000 shares of the company’s common stock. These shares are held directly and, according to a footnote, were purchased in open‑market transactions before he became CFO.
RenovoRx, Inc. appointed Ramtin Agah, M.D., its Chief Medical Officer and Board Chairman, to the newly created role of Executive Chairman, effective February 27, 2026. An offer letter dated March 24, 2026 sets his annualized base salary at $450,000 for at least 30 hours per week.
Dr. Agah is eligible for a discretionary annual bonus of up to 40% of his base salary, with the first bonus payable in 2027 for 2026 performance. He may also receive annual stock options and other equity awards under the 2021 Omnibus Equity Incentive Plan, subject to vesting and continued service. His employment is at will and includes customary confidentiality and intellectual property provisions.
RenovoRx director Marton Laurence, through his Laurence Marton Rollover IRA, bought securities in a private placement. The IRA acquired 4,860 warrants and 9,720 shares of RenovoRx common stock for an aggregate purchase price of $10,000.
The warrants are immediately exercisable at $1.9326 per share and will expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for any calendar quarter in a quarterly or annual report.
RenovoRx, Inc. director and CEO Shaun Bagai reported indirect purchases through The Bagai Family Trust on March 20, 2026. The trust bought 24,300 shares of common stock and 12,150 warrants in a private placement for an aggregate of $25,000.
After these transactions, the trust holds 313,357 shares of common stock and 12,150 warrants, while Bagai also holds 50,983 shares directly. The warrants are exercisable immediately and can be converted into 12,150 shares of common stock at an exercise price of $1.9326 per share.
The warrants expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for any calendar quarter in a quarterly or annual report.